Skip to main content

Taub Rebecca's Form 4 filing

Madrigal Pharmaceuticals, Inc. (MDGL) · filed Dec 12, 2025

Accession no.
0001628280-25-056792
Filed
Dec 12, 2025
Trade date
Dec 10, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 11 non-derivative transactions and 1 derivative transaction. Open-market sales total $10.3M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Taub RebeccaCIK 0001423898Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 10, 2025Common StockMOption exerciseAcquired+18,650$15.80+$294,670479,694Direct
Dec 10, 2025Common StockSSaleDisposed−491$547.76F2−$268,950.16479,203Direct
Dec 10, 2025Common StockSSaleDisposed−369$548.56F3−$202,418.64478,834Direct
Dec 10, 2025Common StockSSaleDisposed−486$550.07F4−$267,334.02478,348Direct
Dec 10, 2025Common StockSSaleDisposed−4,723$550.99F5−$2,602,325.77473,625Direct
Dec 10, 2025Common StockSSaleDisposed−4,410$551.85F6−$2,433,658.5469,215Direct
Dec 10, 2025Common StockSSaleDisposed−3,857$552.81F7−$2,132,188.17465,358Direct
Dec 10, 2025Common StockSSaleDisposed−3,087$553.88F8−$1,709,827.56462,271Direct
Dec 10, 2025Common StockSSaleDisposed−1,027$554.84F9−$569,820.68461,244Direct
Dec 10, 2025Common StockSSaleDisposed−200$555.39−$111,078461,044Direct
Dec 10, 2025Common StockGGiftDisposed−5,455$0.00$0455,589Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 10, 2025Common StockMOption exerciseDisposed−18,650$0.00$018,650Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.16 to $548.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.17 to $549.00, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.38 to $550.37, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $550.39 to $551.38, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.39 to $552.38, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.39 to $553.38, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.39 to $554.33, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.39 to $555.31, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)